Company intelligence / Profile preview

Xcell Therapeutics

Seoul, Seoul Special City, South Koreaxcell.co.kr ↗

Ownership: Private
Employees: ~67
Development stage: Commercial

Overview

Xcell Therapeutics has developed CellCor™, a first-in-class serum-free chemically defined medium used in the expansion of human mesenchymal stem cells. The product is animal component–free, supporting ethical science and sustainability by reducing reliance on bovine serum. The company operates GMP facilities with significant production capacity and aims to be a global leader in regenerative medicine process development.

Modalities: Cell therapyCell culture media
Industry: Chemicals & Materials

Drug pipeline

1 asset

CellCor

Commercial

Partnerships

Participation in Korea’s National Artificial Blood ProjectCollaboration with Amicogen on localizing medium development

Beyond the preview

Go deeper on Xcell Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xcell Therapeutics.

Explore the full profile